Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP lessened its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 19.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 535,952 shares of the company's stock after selling 133,400 shares during the period. Two Sigma Advisers LP owned 0.63% of Syndax Pharmaceuticals worth $7,085,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of SNDX. R Squared Ltd acquired a new position in Syndax Pharmaceuticals during the fourth quarter valued at $26,000. Virtus ETF Advisers LLC grew its stake in Syndax Pharmaceuticals by 18.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock valued at $70,000 after buying an additional 827 shares during the last quarter. Cape Investment Advisory Inc. grew its holdings in Syndax Pharmaceuticals by 157.1% in the 4th quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company's stock valued at $85,000 after buying an additional 3,927 shares during the last quarter. KBC Group NV grew its position in Syndax Pharmaceuticals by 104.8% in the 4th quarter. KBC Group NV now owns 6,954 shares of the company's stock worth $92,000 after purchasing an additional 3,559 shares during the last quarter. Finally, Optimize Financial Inc acquired a new stake in Syndax Pharmaceuticals during the fourth quarter worth about $152,000.

Analysts Set New Price Targets

SNDX has been the topic of a number of research reports. Citigroup reduced their target price on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Wall Street Zen upgraded Syndax Pharmaceuticals to a "sell" rating in a research report on Tuesday, May 6th. HC Wainwright reissued a "buy" rating and set a $51.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. Guggenheim reiterated a "buy" rating and set a $32.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. raised their target price on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a research report on Thursday, March 20th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $35.91.

Syndax Pharmaceuticals Stock Performance

SNDX traded up $0.43 during midday trading on Thursday, hitting $10.55. The stock had a trading volume of 239,941 shares, compared to its average volume of 1,776,016. The business has a fifty day moving average of $11.61 and a 200 day moving average of $13.56. Syndax Pharmaceuticals, Inc. has a 1 year low of $8.58 and a 1 year high of $25.07. The company has a market cap of $907.62 million, a P/E ratio of -2.91 and a beta of 0.82.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.98) earnings per share for the quarter, topping analysts' consensus estimates of ($1.04) by $0.06. The firm had revenue of $20.04 million for the quarter, compared to analysts' expectations of $15.88 million. During the same quarter in the prior year, the company posted ($0.85) earnings per share. The business's revenue for the quarter was up 1900.0% on a year-over-year basis. On average, equities research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).